Alkermes ends Amneal VIVITROL supply pact without penalties
Alkermes plc and Amneal Pharmaceuticals LLC have terminated their Authorized Generic Product Supply Agreement for VIVITROL on July 6, 2026, without incurring penalties. The termination occurred because Amneal failed to meet certain terms and chose not to order batches. Both parties have released mutual claims, concluding the agreement that was originally signed in September 2025.
Amundi Increases Stake in Alkermes plc $ALKS
Amundi significantly increased its stake in Alkermes plc (NASDAQ:ALKS) during the first quarter, nearly doubling its holdings to 64,710 shares valued at approximately $2.29 million. Institutional investors now own 95.21% of the company's stock, which trades between a 52-week low of $25.17 and a high of $55.67. Analysts have a "Moderate Buy" consensus rating with an average price target of $54.56, while recent insider transactions show executives selling shares totaling around $3.9 million over the past 90 days.
Alkermes plc $ALKS Shares Acquired by California State Teachers Retirement System
California State Teachers Retirement System increased its stake in Alkermes plc (NASDAQ:ALKS) by 23.5% in the first quarter, now holding 183,795 shares valued at $6.5 million. Institutional investors own 95.21% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $54.56. Despite insider selling activity, Alkermes shares opened near their 50-day moving average, with the company focused on developing therapies for central nervous system disorders.
Form 4 Alkermes plc. For: 3 August By Investing.com
This article announces that Alkermes plc (ALKS) filed a Form 4 on August 3rd. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders (officers, directors, or beneficial owners of more than 10% of a class of the company's equity securities) to report changes in their ownership of the company's stock. The article is a brief notification from Investing.com and provides no further details about the specific contents of the filing.
Alkermes (ALKS) insider David Gaffin details equity-award stock sales
Alkermes plc insider David Gaffin plans to sell Alkermes common stock through Merrill Lynch, with a total market value of $98,811.72. These sales relate to restricted stock unit and performance share unit awards that vested between 2014 and 2016. Gaffin has also reported monthly open-market sales from April to July 2026, generating proceeds ranging from $70,315.38 to $109,897.02.
Alkermes plc (NASDAQ: ALKS) insider schedules 9,000-share sale after option exercise
An Alkermes plc insider, Craig Hopkinson, plans to sell 9,000 ordinary shares on August 3, 2026, valued at approximately $437,220. These shares originate from employee stock option exercises and vesting of performance and restricted stock awards. The filing also reveals Hopkinson's previous monthly sales of 9,000 shares each from March to July 2026.
Why Alkermes (ALKS) Is Down 7.4% After Q2 Profit Drop And New Equity Shelf Filing
Alkermes plc experienced a 7.4% stock drop after reporting a sharp decline in Q2 2026 net income to US$0.501 million, despite a revenue increase to US$496.01 million. The company also filed a US$311.11 million equity shelf registration, signaling a shift from capital returns to potential financing and compensation needs, raising concerns about profitability and capital allocation for investors.
Why Alkermes (ALKS) Is Down 7.4% After Q2 Profit Drop And New Equity Shelf Filing
Alkermes plc (ALKS) experienced a 7.4% stock drop after reporting a sharp decline in Q2 2026 net income to US$0.501 million from US$87.1 million, despite increased revenue. The company also filed a US$311.11 million shelf registration for 5,900,000 ordinary shares, indicating a shift from capital returns to equity issuance for compensation and potential financing, further complicating its investment narrative focused on profitability and capital allocation.
H.C. Wainwright reiterates Neutral stock rating on Alkermes
H.C. Wainwright reiterated a Neutral rating on Alkermes (NASDAQ:ALKS) shares following strong second-quarter results, where proprietary product sales rose 34% year-over-year, exceeding consensus estimates. Despite impressive sales for products like Vivitrol and the Aristada family, and significant growth in Lybalvi prescriptions and Lumryz sales, the stock is considered overvalued by InvestingPro. The company largely maintained its full-year guidance and is focused on its orexin programs for long-term growth, while also managing increasing costs.
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
Alkermes plc (ALKS) reported break-even earnings for the second quarter of 2026, surpassing the Zacks Consensus Estimate of a 4-cent loss per share, though it was down from 52 cents per share in the prior-year quarter. The company's total revenues reached $496 million, a 27% increase year-over-year and exceeding analysts' expectations, primarily driven by strong product sales. Despite these positive financial results, the stock experienced a decline in pre-market trading, although it has seen an 88.5% rally year-to-date.
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
Alkermes plc reported break-even earnings for Q2 2026, surpassing the Zacks Consensus Estimate of a loss, while revenues of $496 million beat estimates. The company saw a 27% increase in total revenues year-over-year, driven by strong proprietary product sales, yet its stock declined in pre-market trading despite beating revenue expectations. Alkermes also reiterated its full-year 2026 guidance and provided updates on pipeline developments, including the phase III Brilliance studies for alixorexton.
(ALKS) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis of Alkermes Plc (NASDAQ: ALKS), focusing on risk channels and responsive allocation strategies. It highlights strong near-term sentiment with a potential shift to long-term positive bias, noting a significant risk-reward short setup. The analysis outlines three specific trading strategies—position, momentum breakout, and risk hedging—tailored to different risk profiles.
Alkermes beats Q2 estimates, reaffirms revenue guidance
Alkermes plc reported strong second-quarter financial results, surpassing analyst expectations with adjusted earnings per share of $0.00 and revenue of $496.0 million, a 27% increase year-over-year. The company reaffirmed its full-year 2026 revenue guidance, citing strong performance across its proprietary product portfolio, particularly LUMRYZ, LYBALVI, and VIVITROL. Blair Jackson is set to become the new CEO on August 1, 2026.
Alkermes plc (8AK) Q3 2025 Earnings Report - Results, Call & Slides
Alkermes plc (8AK) reported its Q3 2025 earnings, achieving an actual EPS of €0.60, significantly beating the consensus of €0.32. The company also surpassed revenue expectations with €346.21M against an anticipated €313.46M, marking a YoY revenue growth of 4.24%. The next earnings release is estimated for July 28, 2026.
Alkermes plc (8AK) Q3 2024 Earnings Report - Results, Call & Slides
Alkermes plc (8AK) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of €0.63 against a consensus of €0.63 and actual revenue of €332.12M, missing the expected €334.53M. The next earnings date is estimated for July 28, 2026.
Stifel raises Alkermes stock price target on orexin program outlook By Investing.com
Stifel has increased its price target for Alkermes (NASDAQ:ALKS) to $63, up from $45, while maintaining a Buy rating. The adjustment reflects positive expectations for the company's idiopathic hypersomnia program and potential in its ADHD program, both leveraging orexin treatments. Despite the stock trading near its 52-week high and appearing overvalued by some metrics, market expectations for Alkermes' orexin programs have significantly risen.
Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study
Alkermes plc (NASDAQ: ALKS) announced positive interim results from its long-term extension study of alixorexton, showing sustained improvements in wakefulness, daytime sleepiness, cognition, and fatigue for adults with narcolepsy type 1 and 2. Participants in both groups demonstrated continued clinical benefits with a good safety profile. The company plans to present these findings at an upcoming medical meeting, while its stock performance showed a slight decline despite a positive longer-term trend.
Enterprise value to EBIT forward of Alkermes plc – NASDAQ:ALKS
This article focuses on the enterprise value to EBIT forward for Alkermes plc (NASDAQ: ALKS). It appears to be a financial data point or analysis page from TradingView, providing an overview of this specific financial metric for the pharmaceutical company.
Alkermes Plc (ALKS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Alkermes Plc (ALKS) by business segment and by region, with data current as of April 6. The report highlights key product contributions such as VIVITROL, ARISTADA, and LYBALVI, which together account for a significant portion of its revenue. Geographically, the United States generates the vast majority of the company's revenue.
Alkermes (ALKS) director sells 2,000 shares under Rule 10b5-1 plan
Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at $45.10 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Wright directly holds 25,680 Ordinary Shares. The sale amounted to $90,200 and was executed on June 12, 2026, as detailed in the SEC Form 4 filing.
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investors
Alkermes PLC (ALKS) shares surged 4.4% to $44.28 on June 9, 2026, driven by strong momentum despite being identified as significantly overvalued by GuruFocus's GF Value™ methodology. The company holds an above-average GF Score™ of 74/100, though its financial strength and profitability are rated lower, while momentum is exceptionally high. Notably, insiders have sold $1.9 million worth of shares recently, raising concerns about their view on the current valuation.
Alkermes (ALKS) EVP Gaffin sells 2,034 shares under 10b5-1 plan
David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes plc (ALKS), reported an open-market sale of 2,034 Ordinary Shares at an average price of $43.05 per share on June 4, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After the sale, Gaffin directly holds 229,524 Ordinary Shares of Alkermes.
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
Alkermes (ALKS) has seen its shares increase by 21.1% since its last earnings report, outperforming the S&P 500. The company reported a narrower-than-expected Q1 2026 loss and beat revenue estimates, driven by strong sales of its proprietary products like Vivitrol, Aristada, Lybalvi, and the newly acquired Lumryz. Analysts have shown an upward trend in estimate revisions for Alkermes, which currently holds a Zacks Rank #3 (Hold).
Alkermes to participate in the Goldman Sachs 47th annual global healthcare conference
Alkermes plc (ALKS) announced its participation in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference. The company's management will present at the conference on June 11, 2026, at 9:20 a.m. ET. A live webcast of the presentation will be available on the Alkermes investor relations website.
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
Alkermes plc announced it will present 11 posters at the American Society of Clinical Psychopharmacology Annual Meeting. The presentations will feature clinical and real-world data from their psychiatry and orexin portfolios, including commercial medicines LYBALVI and ARISTADA, and investigational orexin 2 receptor agonists. This highlights Alkermes' commitment to advancing research and treatment options for complex psychiatric and neurological conditions.
Alkermes showcases data from psychiatry portfolio and sleep research into real world patient experience at spring 2026 scientific conferences
Alkermes will present data from its psychiatry portfolio and sleep research at various scientific conferences in the spring of 2026. These presentations will include a focus on real-world patient experiences, highlighting the company's commitment to advancing treatments in these therapeutic areas. Specific details about the conferences or the results of the research were not provided.
Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH
Alkermes anticipates increased value from its acquisition of Avadel Pharmaceuticals following positive Phase III results for Lumryz in idiopathic hypersomnia (IH). However, due to a settlement with Jazz Pharmaceuticals, the launch of Lumryz is delayed until 2028. This development positions Alkermes to enter the commercial sleep market.
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023
Alkermes plc is scheduled to report its fourth quarter and year-end financial results on February 16, 2023. The company's recent activities include various SEC filings, insider transactions, and upcoming financial results announcements for different quarters, as tracked by Quantisnow. This report highlights recent analyst ratings and other corporate news surrounding Alkermes.
Alkermes announces positive topline results from Revitalyz phase 3 study evaluating Lumryz
Alkermes plc announced positive topline results from its REVITALYZ Phase 3 study, which evaluated LUMRYZ (sodium oxybate) extended-release for adults with idiopathic hypersomnia. The study met its primary endpoint, demonstrating robust efficacy for the treatment. This development marks a significant step for Alkermes in addressing neurological disorders.
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
Alkermes (ALKS) reported strong first-quarter 2026 results, surpassing both earnings and revenue estimates. This positive financial performance led to a rise in the company's stock. The robust Q1 outcomes indicate a favorable outlook for the pharmaceutical company.
ALKS Financials: Income Statement, Balance Sheet & Cash Flow
This article provides an in-depth financial analysis of Alkermes Plc (ALKS), including its income statement, balance sheet, cash flow statement, and key financial ratios through FY2025. It highlights the company's strong cash generation despite a decline in sales, maintaining high gross margins and a robust balance sheet. The analysis also covers profitability, growth, leverage, liquidity, and returns, along with various financial health indicators like Altman Z-Score and Piotroski F-Score.
Alkermes to Report First Quarter Financial Results on May 5, 2026
Alkermes plc (Nasdaq: ALKS) announced that it will release its first-quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results. Interested parties can access the webcast on the Alkermes website.
Tudor Investment Corp ET AL Takes Position in Alkermes plc $ALKS
Tudor Investment Corp ET AL has acquired a new stake in Alkermes plc (NASDAQ:ALKS), purchasing 56,383 shares valued at approximately $1.69 million in the third quarter. Despite this institutional interest and other funds increasing their positions, insiders have been selling shares, with 159,468 shares worth $5.43 million sold in the last 90 days. Alkermes also missed Q2 earnings estimates, though analysts maintain a "Moderate Buy" rating with an average target price of $44.07.
[ARS] Alkermes plc. SEC Filing
This article reports on an ARS filing by Alkermes plc. (ALKS) on April 6, 2026, accessible as a PDF document. It provides an overview of the filing's low impact and neutral sentiment, along with recent news and other SEC filings related to Alkermes. The company's stock data, including market capitalization and industry, are also detailed.
Alkermes (ALKS) Advances Alixorexton into Phase 3 Trials for Narcolepsy Treatment
Alkermes (ALKS) has advanced alixorexton, an experimental oral treatment, into Phase 3 Brilliance Studies for narcolepsy types 1 and 2, building on positive Phase 2 results. The biotechnology company, with a market capitalization of $5.89 billion, demonstrates strong financial health despite recent insider selling. Investors should consider the company's robust balance sheet and moderate volatility alongside potential regulatory and competitive risks.
Deutsche Bank Adjusts Alkermes Price Target to $42 From $43, Maintains Buy Rating
Deutsche Bank has adjusted its price target for Alkermes plc (ALKS) from $43 to $42, while reiterating a Buy rating on the stock. This update reflects a minor change in the bank's valuation for the biopharmaceutical company. Alkermes recently completed the acquisition of Avadel Pharmaceuticals plc, expanding its presence in the sleep medicine market.
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?
Alkermes (ALKS) is positioned for another earnings beat in its upcoming quarterly report, thanks to a strong history of surpassing analyst estimates and a favorable Zacks Earnings ESP of +1.54%. The company's average surprise in the last two quarters was 21.75%, and with a Zacks Rank #1 (Strong Buy), there's a strong indication of a positive surprise. Investors are advised to watch for the earnings release on February 25, 2026.
Alkermes plc (ALKS) Stock Analysis: Strong Buy Ratings and a Promising 32% Upside Potential
Alkermes plc (NASDAQ: ALKS) is highlighted as a compelling investment due to strong buy ratings and a projected 32.12% upside potential. The biopharmaceutical company, with a market cap of $5.48 billion, focuses on proprietary products for neurological disorders and mental health, demonstrating solid financial health with 4.20% revenue growth and a 22.35% return on equity. Analysts have an average target price of $43.81, driven by its innovative portfolio and strategic collaborations.
Ireland's Alkermes plc buys Avadel Pharmaceuticals plc
Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc for $2.3 billion in cash and debt, incorporating Avadel's FDA-approved narcolepsy drug, LUMRYZ, into its commercial portfolio. This strategic move expands Alkermes' presence in sleep medicine, enhances its pipeline, and is expected to be financially accretive in 2026. The acquisition was financed through a combination of Alkermes' cash reserves and $1.525 billion in term loans, with financial expectations for the combined entity to be released on February 25, 2026.
Ireland's Alkermes plc buys Avadel Pharmaceuticals plc
Alkermes plc has completed its $2.3 billion acquisition of Avadel Pharmaceuticals plc, significantly expanding its commercial portfolio with the FDA-approved narcolepsy drug LUMRYZ. This strategic move strengthens Alkermes' presence in sleep medicine, enhances its commercial capabilities, and is expected to be accretive in 2026. The acquisition also includes Avadel's late-stage pipeline candidate, valiloxybate, and was financed through a combination of cash and term loans.
Public Sector Pension Investment Board Has $21.32 Million Stock Holdings in Alkermes plc $ALKS
The Public Sector Pension Investment Board increased its stake in Alkermes plc by 11.6% in the third quarter, now owning 710,700 shares valued at $21.32 million. Institutional investors collectively own 95.21% of Alkermes stock. Analysts have a "Moderate Buy" consensus rating for Alkermes with an average price target of $44.69, while company insiders have sold approximately $5.03 million worth of shares recently.
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss
Agios Pharmaceuticals reported a narrower-than-expected loss of $1.85 per share in Q4 2025, beating the Zacks Consensus Estimate. Total revenues reached $20 million, significantly exceeding expectations, driven by strong product revenues from Pyrukynd. The company launched its new drug Aqvesme in the U.S. and provided updates on its pipeline, including mitapivat for sickle cell disease.
Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market
Alkermes PLC has announced the completion of its acquisition of Avadel Pharmaceuticals PLC. This strategic move is expected to accelerate Alkermes' entry into the sleep medicine market. The news was reported by Refinitiv.
Alkermes, Inc. , Alkermes, Inc and Alkermes Finance LLC Enters into Credit Agreement
Alkermes plc, along with Alkermes, Inc. and Alkermes Finance LLC, has entered into a credit agreement providing for two senior secured term loan facilities totaling $1.525 billion. These facilities, a $750 million TLA Facility and a $775 million TLB Facility, mature in February 2031 and August 2031, respectively. The company fully borrowed the aggregate amount on the closing date, with interest rates based on the Term SOFR Rate or Alternate Base Rate plus a Secured Net Leverage Ratio-based margin.
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
Alkermes plc has successfully completed its acquisition of Avadel Pharmaceuticals plc, integrating Avadel's FDA-approved narcolepsy treatment, LUMRYZ®, into its commercial portfolio. This strategic move is expected to accelerate Alkermes' entry into the sleep medicine market and bolster its revenue growth profile. The transaction, financed by cash and term loans, is anticipated to be accretive in 2026, with Alkermes planning to provide detailed financial expectations for the combined entity on February 25, 2026.
Alkermes Completes Avadel Acquisition, Expands Sleep Medicine Portfolio
Alkermes has completed its all-cash acquisition of Avadel Pharmaceuticals, adding the FDA-approved narcolepsy treatment LUMRYZ and an early-stage candidate to its portfolio. The acquisition, financed by cash and senior secured term loans totaling $2.275 billion, is expected to be accretive in 2026 and enhances Alkermes' presence in the sleep medicine and rare disease markets. This strategic move aims to broaden Alkermes' revenue base and position it as a more diversified CNS player.
Alkermes (Nasdaq: ALKS) closes Avadel acquisition, adds LUMRYZ and $1.5B loans
Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, gaining the FDA-approved narcolepsy drug LUMRYZ and a specialized commercial team for sleep medicine. The deal involves an all-cash payment of $21.00 per share plus a contingent value right for Avadel shareholders, financed by $750 million from Alkermes' cash and $1.525 billion in new senior secured term loans. This strategic move aims to enhance Alkermes' revenue growth, expand its neuroscience portfolio, and is expected to be accretive in 2026.
Understanding the Setup: (ALKS) and Scalable Risk
This article provides an in-depth analysis of Alkermes Plc (ALKS), highlighting strong near and mid-term sentiment but elevated downside risk in the long term. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The report also details multi-timeframe signal analysis, including support and resistance levels.
Alkermes (Nasdaq:ALKS) - Stock Analysis
This Simply Wall St report provides a stock analysis of Alkermes (Nasdaq:ALKS), a biopharmaceutical company specializing in neurological disorders. It evaluates the company's valuation, future growth prospects, past performance, financial health, dividend policy, management, and ownership, noting that the stock is trading significantly below its estimated fair value. The report highlights potential growth drivers, such as the efficacy of Alixorexton and market expansion opportunities, alongside risks like reliance on a narrow product range and high R&D spending.
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation on Wednesday, February 25, 2026, at 8:00 a.m. ET (1:00 p.m. GMT) to discuss its fourth quarter and year-end 2025 financial results. Management will also provide 2026 financial expectations and a company update. The webcast and accompanying slides will be available on the Investors section of Alkermes' website.
